Cited by 860Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Open access

Eisenberger, Mario A., Blumenstein, Brent A., Crawford, E. David, Miller, Gary, McLeod, David G., Loehrer, Patrick J., Wilding, George, Sears, Kathy, Culkin, Daniel J., Thompson, Ian M., Bueschen, Anton J., Lowe, Bruce A.·1998·New England Journal of Medicine

DOI 10.1056/nejm199810083391504

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate. In the current trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy. METHODS: We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo. Patients were stratified according to the extent of disease and according to performance status. RESULTS: Of the 1387 patients who were enrolled in the trial, 700 were randomly assigned to the flutamide group and 687 to the placebo group. Overall, the incidence of toxic effects was minimal; the only notable differences between the groups were the greater rates of diarrhea and anemia with flutamide. There was no significant difference between the two groups in overall survival (P=0.14). The estimated risk of death (hazard ratio) for flutamide as compared with placebo was 0.91 (90 percent confidence interval, 0.81 to 1.01). Flutamide was not associated with enhanced benefit in patients with minimal disease. CONCLUSIONS: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199810083391504

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Self-citation
Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
The Leuprolide Study Group (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112004 · Cited by 622
The veterans administration cooperative urological research group's studies of cancer of the prostate
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5 · Cited by 595
Designs for group sequential tests
Fleming, T. R., Harrington, D. P., & O’Brien, P. C. (1984) · Controlled Clinical Trials · doi:10.1016/s0197-2456(84)80014-8 · Cited by 354
Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients
Prostate Cancer Trialists' Collaborative Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92163-x · Cited by 320
Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation
Rubinstein, L., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 270

Show all 25 references

Research works printed but not linked: 3

Huggins C, 1941, Cancer Res, 1, 293
10.1002/1097-0142(19931215)72:12+<3834::AID-CNCR2820721714>3.0.CO;2-Z · DOI
Eisenberger MA, 1994, Semin Oncol, 21, 613

Sorted by citations

Items 301–400 of 860

Combined Androgen Blockade: The Case for Bicalutamide
Klotz, L. H., & Schellhammer, P. E. (2005) · Clinical Prostate Cancer · doi:10.3816/cgc.2005.n.002 · Cited by 32
Endocrine prevention and treatment of prostate cancer
Tammela, T. L. J. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.03.002 · Cited by 33
MicroRNAs as prognostic markers in prostate cancer
Süer, İ., Güzel, E., Karataş, Ö. F., Creighton, C. J., Ittmann, M., & Özen, M. (2018) · The Prostate · doi:10.1002/pros.23731 · Cited by 33
Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer
Lloyd, A. J., Penson, D. F., DeWilde, S., & Kleinman, L. (2007) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500992 · Cited by 33
Association of Body Mass Index With Response and Survival in Men With Metastatic Prostate Cancer: Southwest Oncology Group Trials 8894 and 9916
Montgomery, B., Goldman, B. H., Tangen, C. M., Hussain, M., Petrylak, D. P., Page, S. T., Klein, E. A., & Crawford, E. D. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.07.026 · Cited by 33
Self-citation
Regulation of PSA secretion and survival signaling by calcium‐independent phopholipase A 2 β in prostate cancer cells
Nicotera, T. M., Schuster, D. P., Bourhim, M., Chadha, K. C., Klaich, G. M., & Corral, D. A. (2009) · The Prostate · doi:10.1002/pros.20968 · Cited by 33
Intermediate End Point for Prostate Cancer-Specific Mortality Following Salvage Hormonal Therapy for Prostate-Specific Antigen Failure
D'Amico, A. V., Moul, J. W., Carroll, P. R., Cote, K., Sun, L. L., Lubeck, D. P., Renshaw, A. A., Loffredo, M. J., & Chen, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh086 · Cited by 33
Platelet to lymphocyte ratio plays an important role in prostate cancer's diagnosis and prognosis.
Li, F., Hu, H., Gu, S., Chen, X., & Sun, Q. (2015) · PubMed Central · Cited by 33
Analysis of the Molecular Networks in Androgen Dependent and Independent Prostate Cancer Revealed Fragile and Robust Subsystems
Tasseff, R. A., Nayak, S., Salim, S., Kaushik, P., Rizvi, N. F., & Varner, J. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008864 · Cited by 31
Interaction mechanism exploration of R -bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations
Liu, H., An, X., Li, S., Wang, Y., Li, J., & Liu, H. (2015) · Molecular BioSystems · doi:10.1039/c5mb00499c · Cited by 33
Current and emerging treatments in the management of castration-resistant prostate cancer
Shapiro, D. M., & Tareen, B. U. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.59 · Cited by 32
New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone‐releasing hormone agonist
Garnick, M. B., & Mottet, N. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10708.x · Cited by 32
Clinical features of patients who present with metastatic prostate carcinoma and serum prostate‐specific antigen (PSA) levels < 10 ng/mL
Birtle, A. J., Freeman, A., Masters, J. R., Payne, H. A., Harland, S. J., & Contributors to the BAUS Section of Oncology Cancer Registry (2003) · Cancer · doi:10.1002/cncr.11821 · Cited by 32
The Treatment of Prostate Cancer.
Pirtskhalaishvili, G., Hrebinko, R. L., & Nelson, J. B. (2001) · Cancer Practice · doi:10.1111/j.1523-5394.2001.96009.pp.x · Cited by 32
Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases
Miyoshi, Y., Yoneyama, S., Kawahara, T., Hattori, Y., Teranishi, J., Kondo, K., Moriyama, M., Takebayashi, S., Yokomizo, Y., Yao, M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2176-6 · Cited by 31
Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT
Jadvar, H., Velez, E. M., Desai, B., Ji, L., Colletti, P. M., & Quinn, D. I. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223263 · Cited by 31
Conniving for the first time of BiVO4 – rGO/CE-BN and its potential as enhanced electrochemical sensing of non-steroidal anti-androgen drug
Bhuvaneswari, C., Palpandi, K., Amritha, B., Paunkumar, P., Priya, R. L., Raman, N., & Babu, S. G. (2022) · Microchemical Journal · doi:10.1016/j.microc.2022.108174 · Cited by 31
γ‐oryzanol reduces caveolin‐1 and PCGEM1 expression, markers of aggressiveness in prostate cancer cell lines
Hirsch, G. E., Parisi, M. M., Martins, L. A. M., Andrade, C. M. B., Barbé‐Tuana, F. M., & Guma, F. T. C. R. (2015) · The Prostate · doi:10.1002/pros.22960 · Cited by 33
Oncological Outcome of Cytoreductive Radical Prostatectomy in Prostate Cancer Patients With Bone Oligometastases
Lan, T., Chen, Y., Su, Q.-J., & Ye, J.-J. (2019) · Urology · doi:10.1016/j.urology.2019.03.040 · Cited by 30
Treatment options for hormone-refractory prostate cancer.
Chang, S. S. (2007) · Europe PMC (PubMed Central) · Cited by 30
Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer
Chen, W., Zeng, T., Wen, Y.-C., Yeh, H.-L., Jiang, K.-C., Chen, W., Zhang, Q., Huang, J., & Liu, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.004 · Cited by 29
Oral Combination of Cyclophosphamide, Uracil plus Tegafur and Estramustine for Hormone-Refractory Prostate Cancer
Nishimura, K., Nonomura, N., Ono, Y., Nozawa, M., Fukui, T., Harada, Y., Imazu, T., Takaha, N., SUGAO, H., Miki, T., et al. (2000) · Oncology · doi:10.1159/000055296 · Cited by 30
Gleason Score Predicts Androgen Independent Progression after Androgen Deprivation Therapy
Benaim, E. A., Pace, C. M., & Roehrborn, C. G. (2002) · European Urology · doi:10.1016/s0302-2838(02)00238-5 · Cited by 30
Prostate cancer prevention
Nelson, W. G. (2007) · Current Opinion in Urology · doi:10.1097/mou.0b013e3280eb110f · Cited by 32
Incidence and management of hot flashes in prostate cancer.
Spetz, A.-C. E., Zetterlund, E., Varenhorst, E., & Hammar, M. L. (2003) · PubMed · Cited by 30
Serial analysis of resected prostate cancer suggests up‐regulation of type 1 IGF receptor with disease progression
Turney, B. W., Turner, G. D. H., BREWSTER, S. F., & Macaulay, V. M. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09556.x · Cited by 29
Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
van der Zande, K., Oyen, W. J. G., Zwart, W. T., & Bergman, A. M. (2021) · Cancers · doi:10.3390/cancers13174346 · Cited by 32
Recurrent prostate cancer following external beam radiotherapy
Catton, C., Milosevic, M., Warde, P. R., Bayley, A., Crook, J. M., Bristow, R. G., & Gospodarowicz, M. K. (2003) · Urologic Clinics of North America · doi:10.1016/s0094-0143(03)00051-x · Cited by 29
Advances in the Treatment of Metastatic Prostate Cancer
Park, J. C., & Eisenberger, M. A. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.10.010 · Cited by 30
Self-citation
bcl‐2 antagonizes the combined apoptotic effect of transforming growth factor‐β and dihydrotestosterone in prostate cancer cells
Bruckheimer, E. M., & Kyprianou, N. (2002) · The Prostate · doi:10.1002/pros.10143 · Cited by 29
Management of Prostate Cancer After Prostatectomy
Scher, H. I. (1999) · JAMA · doi:10.1001/jama.281.17.1642 · Cited by 29
Inherited Variation in Hormone-Regulating Genes and Prostate Cancer Survival
Lindström, S., Adami, H., Bälter, K. A., Xu, J., Zheng, S. L., Stattin, P. E., Grönberg, H., & Wiklund, F. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0669 · Cited by 28
Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study
Arai, Y., Akaza, H., Deguchi, T., Fujisawa, M., Hayashi, M., Hirao, Y., Kanetake, H., Naito, S., Namiki, M., Tachibana, M., et al. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0409-z · Cited by 28
Androgen Deprivation and Four Courses of Fixed-Schedule Suramin Treatment in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Southwest Oncology Group Study
Hussain, M., Fisher, E. I., Petrylak, D. P., O’Connor, J., Wood, D. P., Small, E. J., Eisenberger, M. A., & Crawford, E. D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1043 · Cited by 28
Self-citation
Quantifying Leukemia
Morley, A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390911 · Cited by 28
Budgetary Impact on a U.S. Health Plan Adopting Abiraterone Acetate Plus Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Sorensen, S. V., Ellis, L., Wu, Y., Hutchins, V., Linnehan, J. E., & Senbetta, M. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.9.799 · Cited by 27
Contemporary agents in the management of metastatic castration-resistant prostate cancer
Kapoor, A., Wu, C. W., Shayegan, B., & Rybak, A. P. (2016) · Canadian Urological Association Journal · doi:10.5489/cuaj.4112 · Cited by 28
Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence- free survival in patients with prostate cancer
Zhong, W., Qin, G., He, H., Han, Z., Liang, Y., Yang, S.-B., Huang, Y., Zhou, L., Fu, H., Jiang, F., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s55432 · Cited by 27
Clinical Outcome of Taiwanese Men With Metastatic Prostate Cancer Compared With Other Ethnic Groups
Chen, C., Tzai, T., Huang, S., Wu, H., Tai, H., Chang, Y.-H., & Pu, Y. (2008) · Urology · doi:10.1016/j.urology.2008.01.026 · Cited by 27
Androgen receptor moonlighting in the prostate cancer microenvironment
Cioni, B., Zwart, W. T., & Bergman, A. M. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0042 · Cited by 27
Recent advances in the treatment of prostate cancer
Kuyu, H., Lee, W. R., Bare, R. L., Hall, M. C., & Torti, F. M. (1999) · Annals of Oncology · doi:10.1023/a:1008385607847 · Cited by 27
ASC-J9®, and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals
Wen, S., Tian, J., Niu, Y., Li, L., Yeh, S., & Chang, C. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.057 · Cited by 26
Ca2+ as a therapeutic target in cancer
Gross, S., Mallu, P., Joshi, H., Schultz, B. M., Go, C. K., & Soboloff, J. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.05.003 · Cited by 29
Nano therapeutic approaches to combat progression of metastatic prostate cancer
Thakur, A. (2021) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2021.100009 · Cited by 26
The Role of Palliative Surgery in Castration-Resistant Prostate Cancer
Heidenreich, A., Porres, D., & Pfister, D. J. K. P. (2015) · Oncology Research and Treatment · doi:10.1159/000442268 · Cited by 26
Approach to Oligometastatic Prostate Cancer
Bernard, B. D., Gershman, B., Karnes, R. J., Sweeney, C. J., & Vapiwala, N. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159241 · Cited by 26
Targeting the Adrenal Gland in Castration-Resistant Prostate Cancer: A Case for Orteronel, a Selective CYP-17 17,20-Lyase Inhibitor
Zhu, H., & Garcia, J. A. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0300-1 · Cited by 25
Accessory Sex Glands in the Male
Prins, G. S., & Lindgren, M. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397175-3.00018-1 · Cited by 26
Current topics and perspectives relating to hormone therapy for prostate cancer
Suzuki, H., Kamiya, N., Imamoto, T., Kawamura, K., Yano, M., Takano, M., Utsumi, T., Naya, Y., & Ichikawa, T. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0830-y · Cited by 26
Germline Predictors of Androgen Deprivation Therapy Response in Advanced Prostate Cancer
Kohli, M., Riska, S. M., Mahoney, D. W., Chai, H. S., Hillman, D. W., Rider, D. N., Costello, B. A., Qin, R., Lamba, J. K., Sahasrabudhe, D. M., et al. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.09.009 · Cited by 26
Hormonotherapy of advanced prostate cancer
Pronzato, P., & Rondini, M. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi913 · Cited by 25
FAILURE AFTER PRIMARY RADIATION OR SURGERY FOR PROSTATE CANCER: DIFFERENCES IN RESPONSE TO ANDROGEN ABLATION
Swanson, G. P., Riggs, M. W., & Earle, J. D. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000132412.74468.57 · Cited by 26
Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer.
Recine, F., & Sternberg, C. N. (2015) · PubMed Central · doi:10.3978/j.issn.2223-4683.2015.04.11 · Cited by 27
Profil épidémiologique, diagnostique, thérapeutique et évolutif du cancer de la prostate au Togo
Tengue, K. K., Kpatcha, T. M., Botcho, G., Leloua, E., Amavi, A. K. A., Sikpa, K. H., Sewa, E. V., Anoukoum, T., Amégbor, K., & Dosseh, E. D. J. (2015) · African Journal of Urology · doi:10.1016/j.afju.2015.06.006 · Cited by 25
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature
Gravis, G., Audenet, F., Irani, J., Timsit, M., Barthélémy, P., Beuzeboc, P., Fléchon, A., Linassier, C., Oudard, S. M., Rébillard, X., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.008 · Cited by 25
Traditional androgen ablation approaches to advanced prostate cancer: new insights.
Rove, K. O., & Crawford, E. D. (2014) · PubMed · Cited by 25
Self-citation
Docetaxel-Prednisolone Combination Therapy for Japanese Patients with Hormone-refractory Prostate Cancer: a Single Institution Experience
Miura, N., Numata, K., Kusuhara, Y., Shirato, A., Hashine, K., & Sumiyoshi, Y. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq100 · Cited by 25
Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy
Kadono, Y., Nohara, T., Ueno, S., Izumi, K., Kitagawa, Y., Konaka, H., Mizokami, A., Onozawa, M., Hinotsu, S., Akaza, H., et al. (2015) · World Journal of Urology · doi:10.1007/s00345-015-1607-3 · Cited by 25
PRACTICE PATTERNS OF CANADIAN UROLOGISTS IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER
Ramsey, E. W., ELHILALI, M. M., Goldenberg, S. L., Nickel, C. J., NORMAN, R., PERREAULT, J. P., & Piercy, B. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67911-6 · Cited by 25
Endocrine approaches in the therapy of prostate carcinoma
d’Ancona, F. C. H., & Debruyne, F. M. J. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi004 · Cited by 25
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences
Collette, L., Studer, U. E., Schröder, F. H., Denis, L. J., & Sylvester, R. J. (2001) · The Prostate · doi:10.1002/pros.1078 · Cited by 25
Prospects for the treatment of endocrine-responsive tumours.
Green, S., & Furr, B. J. A. (1999) · Endocrine Related Cancer · doi:10.1677/erc.0.0060349 · Cited by 25
Horizon scanning for novel therapeutics for the treatment of prostate cancer
Bianchini, D., Zivi, A., Sandhu, S. K., & Bono, J. S. D. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq369 · Cited by 24
Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis
Chen, J., Ni, Y., Sun, G., Liao, B., Zhang, X., Zhao, J., Zhu, S., Wang, Z., Shen, P., & Zeng, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.519388 · Cited by 24
Discovery of an Orally-Active Nonsteroidal Androgen Receptor Pure Antagonist and the Structure-Activity Relationships of Its Derivatives
Tachibana, K., Imaoka, I., Shiraishi, T., Yoshino, H., Nakamura, M., Ohta, M., Kawata, H., Taniguchi, K., Ishikura, N., Tsunenari, T., et al. (2008) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.56.1555 · Cited by 24
The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer
Kim, J., Park, J. S., & Ham, W. S. (2017) · Korean journal of urology · doi:10.4111/icu.2017.58.5.307 · Cited by 24
How Large Are Your G -Values? Try Gosset’s Guinnessometrics When a Little “ p ” Is Not Enough
Ziliak, S. T. (2019) · The American Statistician · doi:10.1080/00031305.2018.1514325 · Cited by 23
Management of patients with an increasing prostate-specific antigen after radical prostatectomy
Khan, M. A., & Partin, A. W. (2004) · Current Urology Reports · doi:10.1007/s11934-004-0035-5 · Cited by 23
Androgen Deprivation in Prostate Cancer — Step by Step
Albertsen, P. C. (2009) · New England Journal of Medicine · doi:10.1056/nejme0901737 · Cited by 24
Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer
Binder, M., Zhang, B., Hillman, D. W., Kohli, R., Kohli, T., Lee, A., & Kohli, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071097 · Cited by 23
Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness
Kang, S. K., Mali, R. D., Prabhu, V., Ferket, B. S., & Loeb, S. (2021) · Radiology · doi:10.1148/radiol.2021204321 · Cited by 23
Phase angle and extracellular water-to-total body water ratio estimated by bioelectrical impedance analysis are associated with levels of hemoglobin and hematocrit in patients with diabetes
Hori, T., Nakamura, S., Yamagami, H., Yasui, S., Hosoki, M., Hara, T., Mitsui, Y., Masuda, S., Kurahashi, K., Yoshida, S., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14724 · Cited by 23
Treating Prostate Cancer in Elderly Men: How Does Aging Affect the Outcome?
Shelke, A. R., & Mohile, S. G. (2011) · Current Treatment Options in Oncology · doi:10.1007/s11864-011-0160-6 · Cited by 23
Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
Bhattasali, O., Chen, L. N., Tong, M. C. F., Lei, S., Collins, B. T., Krishnan, P., Kalhorn, C. G., Lynch, J. H., Suy, S., Dritschilo, A., et al. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00293 · Cited by 23
Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy
Huang, S., Bao, B., Wu, M., Choueiri, T. K., Goggins, W. B., Liu, C., Huang, C., Pu, Y., Yu, C., Wu, T. T., et al. (2011) · The Aging Male · doi:10.3109/13685538.2011.580398 · Cited by 23
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
Collins, R., Trowman, R., Norman, G., Light, K., Birtle, A. J., Fenwick, E. A. L., Palmer, S., & Riemsma, R. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603287 · Cited by 23
Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer
Gołąbek, T., Belsey, J., Drewa, T. A., Kołodziej, A., Skoneczna, I. A., Milecki, P., Dobruch, J. T., Słojewski, M., & Chłosta, P. L. (2016) · Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication · doi:10.5173/ceju.2016.812 · Cited by 22
Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells
Samiea, A., Yoon, J. S. J., Ong, C. J., Zoubeidi, A., Chamberlain, T. C., & Mui, A. (2020) · Prostate Cancer · doi:10.1155/2020/5305306 · Cited by 22
Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy
Miyamoto, S., Ito, K., Miyakubo, M., Suzuki, R., Yamamoto, T., Suzuki, K., Suzuki, K., & Yamanaka, H. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.47 · Cited by 22
The Role of Hormonal Treatment in Prostate Cancer
Flüchter, S. H., Weiser, R., & Gamper, C. (2007) · Springer eBooks · doi:10.1007/978-3-540-40901-4_13 · Cited by 22
Luteinising hormone-releasing hormone antagonists in prostate cancer therapy
Msaouel, P., Diamanti, E., Tzanela, M., & Koutsilieris, M. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.2.285 · Cited by 22
Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer
McCarthy, H. O., Coulter, J. A., Worthington, J., Robson, T., & Hirst, D. G. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1045 · Cited by 22
Flavones: The Apoptosis in Prostate Cancer of Three Flavones Selected as Therapeutic Candidate Models
Jeong, S. H., Kim, H. H., Park, M. Y., Bhosale, P. B., Abusaliya, A., Won, C., Park, K., Kim, E.-H., Heo, J., Kim, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119240 · Cited by 22
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel
Peer, A., Gottfried, M., Sinibaldi, V. J., Carducci, M. A., Eisenberger, M. A., Sella, A., Leibowitz‐Amit, R., Berger, R., & Keizman, D. (2013) · The Prostate · doi:10.1002/pros.22765 · Cited by 21
Self-citation
Highlights of contemporary issues in the medical management of prostate cancer
Sternberg, C. N. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00023-9 · Cited by 21
Intravenous therapies for castration-resistant prostate cancer: Toxicities and adverse events
Singer, E. A., & Srinivasan, R. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.09.003 · Cited by 21
Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer
Yoshino, H., Sato, H., Shiraishi, T., Tachibana, K., Emura, T., Honma, A., Ishikura, N., Tsunenari, T., Watanabe, M., Nishimoto-Kakiuchi, A., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.10.023 · Cited by 21
Understanding heterogeneity of treatment effect in prostate cancer
Aly, A., Mullins, C. D., & Hussain, A. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000172 · Cited by 20
Retrospective Analysis of an Oral Combination of Dexamethasone, Uracil plus Tegafur and Cyclophosphamide for Hormone-refractory Prostate Cancer
Hatano, K., Nonomura, N., Nishimura, K., Kawashima, A., Mukai, M., Nagahara, A., Nakai, Y., Nakayama, M., Takayama, H., Tsujimura, A., et al. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq178 · Cited by 20
The role of palliative surgery in castration-resistant prostate cancer
Piper, C., Porres, D., Pfister, D. J. K. P., & Heidenreich, A. (2014) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000078 · Cited by 20
An�sthesie bei Patienten mit Parkinson-Erkrankung
Kalenka, A., & Hinkelbein, J. (2005) · Der Anaesthesist · doi:10.1007/s00101-005-0840-3 · Cited by 20
Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
Calcagno, F., Nguyen, T., Dobi, E., Villanueva, C., Curtit, E., Kim, S. C. H., Montcuquet, P., Kleinclauss, F., Pivot, X. B., & Thiery-Vuillemin, A. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7256 · Cited by 20
Three-weekly Docetaxel with Prednisone is Feasible for Japanese Patients with Hormone-refractory Prostate Cancer: A Retrospective Comparative Study with Weekly Docetaxel Alone
Shimazui, T., Kawai, K., Miyanaga, N., Kojima, T., Sekido, N., Hinotsu, S., Oikawa, T., Joraku, A., & Akaza, H. (2007) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hym071 · Cited by 20
Hormonal therapy for prostate cancer: past, present and future
El-Rayes, B. F., & Hussain, M. (2002) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2.1.37 · Cited by 20
BENIGN AND MALIGNANT NEOPLASMS OF PROSTATE
Walsh, P. C. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)68052-4 · Cited by 20
How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?
Turco, F., Prima, L. D., Pisano, C., Poletto, S., Filippis, M. D., Crespi, V., Farinea, G., Cani, M., Calabrese, M., Saporita, I., et al. (2023) · Research and Reports in Urology · doi:10.2147/rru.s350793 · Cited by 20
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy
Monk, J. P., Halabi, S., Picus, J., Hussain, A., Philips, G. K., Kaplan, E. B., Ahles, T. A., Gu, L., Vogelzang, N. J., Kelly, W. K., et al. (2011) · Cancer · doi:10.1002/cncr.26732 · Cited by 19
Current perspectives in the treatment of advanced prostate cancer
Valdespino, V., Tsagozis, P., & Pisa, P. (2007) · Medical Oncology · doi:10.1007/s12032-007-0017-9 · Cited by 19
The Diffusion of Docetaxel in Patients With Metastatic Prostate Cancer
Unger, J. M., Hershman, D. L., Martin, D. P., Etzioni, R. B., Barlow, W. E., LeBlanc, M. L., & Ramsey, S. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju412 · Cited by 19
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study
Iguchi, T., Tamada, S., Kato, M., Yasuda, S., Machida, Y., Ohmachi, T., Ishii, K., Iwata, H., Yamamoto, S., Kanamaru, T., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01554-3 · Cited by 19

Authors: Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., Bueschen, A. J., & Lowe, B. A.
Affiliations: Johns Hopkins Hospital (US)
SWOG Cancer Research Network (US)
University of Colorado Denver (US)
Walter Reed National Military Medical Center (US)
University of Wisconsin–Madison (US)
University of Oklahoma Health Sciences Center (US)
University of Alabama at Birmingham (US)
Oregon Health & Science University (US)
ORCID: Eisenberger, Mario A.
Blumenstein, Brent A.
Crawford, E. David
McLeod, David G.
Loehrer, Patrick J.
Wilding, George
Culkin, Daniel J.
Thompson, Ian M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-10-08
Volume: 339
Issue: 15
Pages: 1036-1042
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199810083391504
OpenAlex: W2003985632
Cited by: 859
References: 25
Citations by year: 2026: 2 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 20 · 2021: 15 · 2020: 21 · 2019: 26 · 2018: 25 · 2017: 23 · 2016: 34 · 2015: 52 · 2014: 49 · 2013: 51 · 2012: 37
FWCI: 37.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (2u10ca038926-25)
National Cancer Institute (CA-32102, CA 42777, U10CA032102, U10CA042777, CA 38926)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: metastatic prostate cancer, bilateral orchiectomy, flutamide, combined androgen blockade, leuprolide, antiandrogen therapy, overall survival, adverse effects, anemia, diarrhea
MeSH terms: Adenocarcinoma, Adult, Aged, Aged, 80 and over, Androgen Antagonists, Bone Neoplasms, Combined Modality Therapy, Double-Blind Method, Flutamide, Humans, Male, Middle Aged, Orchiectomy, Prostatic Neoplasms, Soft Tissue Neoplasms, Survival Analysis, Prostate-Specific Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks